An estimated 64 million Americans have elevated levels of lipoprotein(a), or Lp(a), a type of cholesterol that can increase the risk of heart attack and other cardiovascular problems. Having high Lp(a ...

China NMPA approves Rona Therapeutics’ IND application for RN1871, a novel AGT-targeting siRNA drug for hypertension: Shanghai, China Tuesday, April 22, 2025, 18:00 Hrs [IST] Ro ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration’s ...

Silexion Therapeutics (SLXN) announced a strategic collaboration with Catalent (CTLT). Under the agreement, Catalent will conduct formulation ...

Rona Therapeutics is committed to developing the best and first-in-class siRNA drugs with differentiation and innovation to address unmet needs and improve outcome in cardiovascular diseases ...

Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug ...